ESR1 and breast carcinoma: (2008) determined that RET and ERα pathway share a functional crosstalk in luminal breast cancer cells and RET expression can be enhanced upon stimulation of the ERα pathway (153), suggesting that RET-positive luminal breast cancers may benefit from RET inhibition.